Ge Long Hui A P P·2025-09-15 08:45Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for a new indication of the drug FCN-437c (commercial name: Fuzhuoning) for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] Group 1 - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1] - FCN-437c is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights owned by the group [1] - The drug is characterized as an oral, potent, highly selective, and structurally novel small molecule, and was included in the national "Major New Drug Creation" science and technology major project in 2018 [1]